J&J Says Two Drugs Are Better than One in Pretreated Myeloma

J&J says two drugs are better than one in pretreated myeloma

Combining Johnson & Johnson's multiple myeloma therapies Talvey and Tecvayli shows promise in a hard-to-treat form of multiple myeloma

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA

Anti-BCMA and Anti-GPRC5D BiTEs Show Similar Efficacy in Multiple Myeloma

A real-world analysis of teclistamab, elranatamab, and talquetamab showed comparable outcomes in relapsed or refractory multiple myeloma.

Talvey And Tecvayli Combo Shows Strong, Durable Responses In High-Risk Multiple Myeloma With Extramedullary Disease In Phase II Trial - Data Intelligence

Credit: David A Litman

Combination myeloma treatment shows promise in trial

Most people with hard-to-treat multiple myeloma who were given a combination treatment of Talvey (talquetamab-tgvs) and Tecvayli (teclistamab-cqyv) in a clinical trial were alive and free from disease progression after a year, data showed. Johnson & Johnson, which markets both therapies, detailed the findings at the 2025 European Hematology Association Congress, held June 12-15 in Milan, in a presentation titled, “Phase 2 Study of talquetamab + …